Fluoroquinolone-resistant acute prostatitis requiring hospitalization after transrectal prostate biopsy: effect of previous fluoroquinolone use as prophylaxis or long-term treatment

Int Urol Nephrol. 2012 Feb;44(1):19-27. doi: 10.1007/s11255-011-9980-3. Epub 2011 May 6.

Abstract

Objectives: This study aims to scrutinize the hospitalized patients with the diagnosis of acute prostatitis after transrectal ultrasound-guided biopsy of the prostate (TRUSBP) focusing their history of previous antibiotic use, clinical pictures, microbiologic features, and resistance patterns of the isolates.

Patients and methods: A retrospective evaluation of the records between 2005 and 2010 revealed 13 patients. All patients received ciprofloxacin 500 mg twice a day starting from the day before TRUSBP for 5 days.

Results: Positive 13 urine and 7 blood samples (Escherichia coli in 12 patients, Enterococcus species in one) were evaluated for resistance patterns. All were resistant to fluoroquinolones. Extended spectrum beta-lactamase producing E. coli isolated in 4 patients were treated with carbapenems. Empirical ceftriaxone was shifted to carbapenem (4 patients), vancomycin (1 patient). Empirical carbapenem was maintained in 5 patients. Seven patients with elevated PSA received fluoroquinolones for 4 weeks before TRUSBP on the assumption that they had subclinical infectious prostatitis. Previous exposure to fluoroquinolones did not lead to important differences in respect to the studied parameters.

Conclusions: The prompt initiation of effective treatment is essential to decrease morbidity and mortality. Empirical treatment would be a second or third generation cephalosporins, or carbapenems according to clinical severity of patients.

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use*
  • Anti-Infective Agents / therapeutic use
  • Antibiotic Prophylaxis / adverse effects*
  • Biopsy / adverse effects*
  • Carbapenems / therapeutic use
  • Ceftriaxone / therapeutic use
  • Ciprofloxacin / therapeutic use
  • Drug Resistance, Multiple, Bacterial*
  • Enterococcus
  • Escherichia coli
  • Escherichia coli Infections / drug therapy
  • Fluoroquinolones / therapeutic use*
  • Hospitalization
  • Humans
  • Length of Stay
  • Male
  • Middle Aged
  • Prostate / pathology
  • Prostate-Specific Antigen / blood
  • Prostatitis / blood
  • Prostatitis / drug therapy*
  • Prostatitis / microbiology*
  • Retrospective Studies
  • Vancomycin / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Carbapenems
  • Fluoroquinolones
  • Ciprofloxacin
  • Vancomycin
  • Ceftriaxone
  • Prostate-Specific Antigen